Fiche centre
Universitätsklinikum Hamburg-Eppendorf
Hamburg — Germany
Essais liés6clinical trials
VilleHamburglocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03950076
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Dapagliflozin 10 mg/day (oral) | Maladie rénale chronique | Phase 3 | NCT05374291 | The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | ACTIVE_NOT_RECRUITING |
| Edoxaban | Accident vasculaire cérébral | Phase 4 | NCT03950076 | EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) | COMPLETED |
| KYV-101 anti-CD19 CAR-T cell therapy | Lupus | Phase 1/2 | NCT06342960 | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | TERMINATED |
| Autologous Hematopoietic Stem Cell Transplantation | SEP | Phase 2 | NCT04971005 | COAST — Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial | TERMINATED |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| Standard lymphodepletion regimen | Myasthénie | Phase 2/3 | NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | RECRUITING |